Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Influenza C virus surveillance during the first influenza A (H1N1) 2009 pandemic wave in Catalonia, Spain.

Antón A, Marcos MA, Codoñer FM, de Molina P, Martínez A, Cardeñosa N, Godoy P, Torner N, Martínez MJ, Ramón S, Tudó G, Isanta R, Gonzalo V, de Anta MT, Pumarola T.

Diagn Microbiol Infect Dis. 2011 Apr;69(4):419-27. doi: 10.1016/j.diagmicrobio.2010.11.006.

PMID:
21396539
2.

Selection and viral load kinetics of an oseltamivir-resistant pandemic influenza A (H1N1) virus in an immunocompromised patient during treatment with neuraminidase inhibitors.

Antón A, López-Iglesias AA, Tórtola T, Ruiz-Camps I, Abrisqueta P, Llopart L, Marcos MÁ, Martínez MJ, Tudó G, Bosch F, Pahissa A, de Anta MT, Pumarola T.

Diagn Microbiol Infect Dis. 2010 Nov;68(3):214-9. doi: 10.1016/j.diagmicrobio.2010.08.003.

PMID:
20955912
3.

Double (V27A/S31N) mutant 2009 pandemic influenza A (H1N1) virus isolated from adamantane non-treated inmunocompetent child.

Antón A, Marcos MA, Martínez MJ, Ramón S, Isanta R, de Molina P, de Anta MT, Pumarola T.

Diagn Microbiol Infect Dis. 2010 May;67(1):114-5. doi: 10.1016/j.diagmicrobio.2009.12.019. Epub 2010 Mar 12.

PMID:
20227229
4.

Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens.

Alvarez-Martínez MJ, Miró JM, Valls ME, Moreno A, Rivas PV, Solé M, Benito N, Domingo P, Muñoz C, Rivera E, Zar HJ, Wissmann G, Diehl AR, Prolla JC, de Anta MT, Gatell JM, Wilson PE, Meshnick SR; Spanish PCP Working Group.

Diagn Microbiol Infect Dis. 2006 Oct;56(2):153-60. Epub 2006 May 4.

PMID:
16678378
5.

Ciprofloxacin, salicylate, and 2,4-dinitrophenol decrease production of AmpC-type beta-lactamase in two Citrobacter freundii clinical isolates.

Tavío MM, Perilli M, Vila J, Becerro P, Ruiz J, Amicosante G, De Anta MT.

Microb Drug Resist. 2005 Fall;11(3):225-31.

PMID:
16201924
6.

Characterization of sparfloxacin-resistant mutants of Staphylococcus aureus obtained in vitro.

Ruiz J, Sierra JM, De Anta MT, Vila J.

Int J Antimicrob Agents. 2001 Aug;18(2):107-12.

PMID:
11516932
7.

In vitro selected fluoroquinolone-resistant mutants of Citrobacter freundii: analysis of the quinolone resistance acquisition.

Tavío M, Vila J, Ruiz J, Amicosante G, Franceschini N, Martín-Sánchez AM, de Anta MT.

J Antimicrob Chemother. 2000 Apr;45(4):521-4.

PMID:
10747831
8.

Analysis of the mechanisms of quinolone resistance in clinical isolates of citrobacter freundii

Navia MM, Ruiz J, Ribera A, de Anta MT, Vila J.

J Antimicrob Chemother. 2000 Apr;45(4):556. No abstract available.

PMID:
10747842
9.

Analysis of the mechanisms of quinolone resistance in clinical isolates of Citrobacter freundii.

Navia MM, Ruiz J, Ribera A, de Anta MT, Vila J.

J Antimicrob Chemother. 1999 Dec;44(6):743-8. Erratum in: J Antimicrob Chemother 2000 Apr;45(4):556.

PMID:
10590274
10.

Increase in quinolone resistance in a Haemophilus influenzae strain isolated from a patient with recurrent respiratory infections treated with ofloxacin.

Vila J, Ruiz J, Sanchez F, Navarro F, Mirelis B, de Anta MT, Prats G.

Antimicrob Agents Chemother. 1999 Jan;43(1):161-2.

11.

Permanent response to alpha-interferon therapy in chronic hepatitis C is preceded by rapid clearance of HCV-RNA from serum.

Ampurdanés S, Olmedo E, Maluenda MD, Forns X, López-Labrador FX, Costa J, Sánchez-Tapias JM, de Anta MT, Rodés J.

J Hepatol. 1996 Dec;25(6):827-32.

PMID:
9007709
12.

Prevention and control of nosocomial infections in Spain: current problems and future trends.

Trilla A, Vaqué J, Roselló J, Salles M, Marco F, Prat A, Bayas JM, de Anta MT, Asenjo MA.

Infect Control Hosp Epidemiol. 1996 Sep;17(9):617-22.

PMID:
8880236
13.

Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli.

Vila J, Ruiz J, Goñi P, De Anta MT.

Antimicrob Agents Chemother. 1996 Feb;40(2):491-3.

Supplemental Content

Loading ...
Support Center